1. Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation in Turkey: A Microsimulation Approach 
Mete Saylan, MD, M.J. Treur, R. Postema, N. Dilbaz, H. Savas, B.M. Heeg, P.B. Drost 
Value in Health Regional Issues 
Volume 2, Issue 2, Pages (September 2013)
DOI: /j.vhri
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1 Schematic model representation.
Value in Health Regional Issues 2013 2, DOI: ( /j.vhri )
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2 Treatment sequence strategies. T3, triiodothyronine.
Value in Health Regional Issues 2013 2, DOI: ( /j.vhri )
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Time until next episode per number of prior episodes. Data points are from Solomon et al. [35]. Lines represent Weibul survival curve fits.
Value in Health Regional Issues 2013 2, DOI: ( /j.vhri )
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

5. Fig. 4
Scatter plot of comparison adjunctive aripiprazole with adjunctive quetiapine and adjunctive olanzapine. QALY, quality-adjusted life-year; TL, Turkish lira.
Value in Health Regional Issues 2013 2, DOI: ( /j.vhri )
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

6. Fig. 5
Cost-effectiveness acceptability curves. QALY, quality-adjusted life-year; TL, Turkish lira.
Value in Health Regional Issues 2013 2, DOI: ( /j.vhri )
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions